Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Absorption, Metabolism, and Excretion of [14C]ARV-471 in Healthy Adult Participants
NCT05930925Phase 1Completed
- Sponsor
- Pfizer
- Start
- Jun 2023
- Primary completion
- Jul 2023
- Modality
- Bivalent/Multivalent Binders, PROTACs (E3 ligase recruitment)
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of vepdegestrant in breast cancer (2 arms), sponsored by Pfizer. Primary endpoints: Area Under the Curve From Time Zero to Extrapolated Infinite Time, Maximum Observed Plasma Concentration and 9 more. Started Jun 2023; status: completed.
02
Drugs
vepdegestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05930925.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05930925.